Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination–proficient ovarian cancer
BACKGROUND Treatment of tubo-ovarian high-grade serous carcinoma (HGSC) includes cytoreductive surgery, platinum-based chemotherapy, and often poly(ADP-ribose) polymerase (PARP) inhibitors. While homologous recombination (HR) deficiency is a well-established predictor of therapy sensitivity, over 50...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society for Clinical Investigation
2025-07-01
|
| Serier: | The Journal of Clinical Investigation |
| Fag: | |
| Online adgang: | https://doi.org/10.1172/JCI189511 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
